Mylan N.V.
(NASDAQ : MYL)

( )
MYL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
-1.02%163.842.8%$373.91m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
1.00%23.692.1%$248.00m
ZTSZoetis, Inc. Class A
-0.87%94.441.9%$234.97m
MYLMylan N.V.
-2.73%35.943.2%$217.20m
TXMDTherapeuticsMD, Inc.
-4.46%4.7125.8%$15.58m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
0.39%33.422.0%$10.13m
ABEOAbeona Therapeutics, Inc.
-17.63%7.717.9%$5.25m
TAROTaro Pharmaceutical Industries Ltd.
-1.23%102.166.3%$5.20m
PETXAratana Therapeutics, Inc.
-4.65%6.368.7%$3.56m
KINKindred Biosciences, Inc.
-3.96%12.870.3%$2.98m
LFVNLifeVantage Corporation
0.34%11.893.3%$1.07m
CPHIChina Pharma Holdings, Inc.
-9.06%0.300.1%$0.73m
JAGXJaguar Animal Health, Inc.
-3.23%0.459.8%$0.62m

Company Profile

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The Corporate or Other segment covers other expenses not directly attributable to the segments and certain intercompany transactions of the firm. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.